Tradestie Institutional Equity Comparison Engine

SLN vs CGEN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CGEN Overall Edge

CGEN Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Compugen Ltd (CGEN) driven by superior Valuation, Growth & Margin while SLN counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, SLN trades at N/M Forward P/E with -11905.9% operating margin (+197.2% YoY revenue) versus CGEN at 12.4x Forward P/E and 41.3% operating margin (+102.1% YoY). In options structure, SLN sits in UNCLASSIFIED (50th %ile IV; Dealer Gamma Walls on Pro) against CGEN sits in BREAKDOWN (57th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CGEN
SLN N/M vs CGEN 12.4x Fwd P/E
Growth & Margin Winner CGEN
Op Margin -11905.9% vs 41.3% ยท YoY +197.2% vs +102.1%
Momentum & Technical Winner SLN
1Y +189.9% vs +23.2% ยท 52W Pos 100% vs 33%
Options & Structure Winner SLN
UNCLASSIFIED (50th %ile IV) vs BREAKDOWN (57th %ile IV)
SLN NASDAQ
Silence Therapeutics Plc American Depository Share
Pharmaceutical Preparations
$19.80
+0.0% 1D
Market Cap $1.2B
1M Return +1.12%
1Y Return +189.9%
Forward P/E N/M
Unified AI Score
45.2 / 100 HOLD
Tech 25.0 Fund 34.0 Flow 50.0 Mom 30.0
CGEN NASDAQ
Compugen Ltd
Biological Products, (No Diagnostic Substances)
$2.02
-0.98% 1D
Market Cap $193.2M
1M Return +2.54%
1Y Return +23.17%
Forward P/E 12.4x
Unified AI Score
49.8 / 100 HOLD
Tech 53.0 Fund 52.0 Flow 55.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SLN +189.9% CGEN +23.17% Spread: +166.73 pp (SLN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
SLN TTM Op. Margin: -11905.9% CGEN TTM Op. Margin: 41.3%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SLN vs CGEN. Trailing 12-month operating profitability (SLN -11905.9% vs CGEN 41.3%) and valuation multiples (SLN N/M vs CGEN 12.4x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SLN (4) vs CGEN (6)
Institutional Metric SLN CGEN Criterion Row Winner
Market Capitalization Scale $1.2B $193.2M Larger Scale SLN
Trailing P/E Ratio Valuation N/M 5.2x Lower Multiple CGEN
Forward P/E Ratio Valuation N/M 12.4x Lower Multiple CGEN
Revenue Growth (YoY) Growth +197.2% +102.1% Higher Growth SLN
Operating Margin (TTM) Profitability -11905.9% 41.3% Higher Margin CGEN
Net Profit Margin Profitability 0.0% 47.9% Higher Margin CGEN
Return on Equity (ROE) Capital Efficiency -35.6% 57.2% Higher ROE CGEN
52-Week Range Position Momentum 100% ($4โ€“$20) 33% ($1โ€“$3) Stronger Trend SLN
Beta / 30D Volatility Risk Regime 1.92ฮฒ ยท 4% Vol 1.44ฮฒ ยท 62% Vol Lower Realized Risk SLN
Unified Institutional Score Composite Signal 45.2 / 100 (HOLD) 49.8 / 100 (HOLD) Higher Composite CGEN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SLN vs CGEN Buy Guide
SLN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 50th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live SLN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CGEN BREAKDOWN
143d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 57th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CGEN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SLN nor CGEN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.